EP2424507A4 - Compositions and methods for treating insulin resistance and diabetes mellitus - Google Patents

Compositions and methods for treating insulin resistance and diabetes mellitus

Info

Publication number
EP2424507A4
EP2424507A4 EP10770213A EP10770213A EP2424507A4 EP 2424507 A4 EP2424507 A4 EP 2424507A4 EP 10770213 A EP10770213 A EP 10770213A EP 10770213 A EP10770213 A EP 10770213A EP 2424507 A4 EP2424507 A4 EP 2424507A4
Authority
EP
European Patent Office
Prior art keywords
insulin
compositions
treatment
methods
diabetes resistance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10770213A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2424507A1 (en
Inventor
Richard L Watson
Anthony B Wood
Gregory J Archambeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microdiffusion Inc
Original Assignee
Microdiffusion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microdiffusion Inc filed Critical Microdiffusion Inc
Publication of EP2424507A1 publication Critical patent/EP2424507A1/en
Publication of EP2424507A4 publication Critical patent/EP2424507A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP10770213A 2009-04-27 2010-04-27 Compositions and methods for treating insulin resistance and diabetes mellitus Withdrawn EP2424507A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17313409P 2009-04-27 2009-04-27
PCT/US2010/032620 WO2010126908A1 (en) 2009-04-27 2010-04-27 Compositions and methods for treating insulin resistance and diabetes mellitus

Publications (2)

Publication Number Publication Date
EP2424507A1 EP2424507A1 (en) 2012-03-07
EP2424507A4 true EP2424507A4 (en) 2012-10-24

Family

ID=43032520

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10770213A Withdrawn EP2424507A4 (en) 2009-04-27 2010-04-27 Compositions and methods for treating insulin resistance and diabetes mellitus

Country Status (9)

Country Link
EP (1) EP2424507A4 (https=)
JP (2) JP2012525396A (https=)
CN (1) CN102413817B (https=)
AU (1) AU2010241736B2 (https=)
BR (1) BRPI1013992A2 (https=)
CA (1) CA2758738A1 (https=)
IL (1) IL215925A0 (https=)
MX (1) MX2011011333A (https=)
WO (1) WO2010126908A1 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
KR101452915B1 (ko) 2006-05-04 2014-10-21 베링거 인겔하임 인터내셔날 게엠베하 다형태
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
US8399006B2 (en) 2009-01-29 2013-03-19 Forsight Vision4, Inc. Posterior segment drug delivery
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
JP6111194B2 (ja) 2010-08-05 2017-04-05 フォーサイト・ビジョン フォー・インコーポレーテッド 組み合わせ薬物送達方法および装置
SI2600812T1 (sl) 2010-08-05 2021-12-31 ForSight Vision4, Inc., Naprava za zdravljenje očesa
EP3861969A1 (en) 2010-08-05 2021-08-11 ForSight Vision4, Inc. Injector apparatus for drug delivery
JP2013533320A (ja) 2010-08-12 2013-08-22 レバレジオ コーポレイション タウオパチーを治療するための組成物および方法
AR083878A1 (es) * 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
ES2777890T3 (es) * 2010-11-15 2020-08-06 Boehringer Ingelheim Int Terapia antidiabética vasoprotectora y cardioprotectora
WO2012068549A2 (en) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US20120263764A1 (en) * 2011-04-13 2012-10-18 Revalesio Corporation Compositions and methods for inhibiting and/or modulating effector t-cells involved in inflammatory neurodegenerative disease
EP4249059B1 (en) 2011-06-28 2025-07-30 ForSight Vision4, Inc. An apparatus for collecting a sample of fluid from a reservoir chamber of a therapeutic device for the eye
RS61758B1 (sr) 2011-09-16 2021-05-31 Forsight Vision4 Inc Aparati za razmenu tečnosti
US10010448B2 (en) 2012-02-03 2018-07-03 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
JP6159584B2 (ja) * 2012-06-14 2017-07-05 松本　高明 輸液、輸液の製造方法および輸液装置
CH706747A2 (de) * 2012-07-17 2014-01-31 Hanspeter Steffen Verfahren zur Hydration, Straffung und Pflege der Haut, zur Behandlung von Dermatosen, Sonnenbrand und genereller Wunden mit Diamantelektroden hergestelltem Elektrolysewasser.
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
CA2905496A1 (en) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
ES2972168T3 (es) 2013-03-28 2024-06-11 Forsight Vision4 Inc Implante oftálmico para administración de sustancias terapéuticas
WO2015099201A1 (ja) * 2013-12-27 2015-07-02 アクア・ゼスト株式会社 ナノバブル含有組成物およびその用途
US20170056438A1 (en) * 2014-10-17 2017-03-02 Aqua Zest Corporation Nanobubble-containing composition and use thereof
EP3169289B1 (en) 2014-07-15 2020-04-15 ForSight Vision4, Inc. Ocular implant delivery device
BR112017002466A2 (pt) 2014-08-08 2017-12-05 Forsight Vision4 Inc formulações estáveis e solúveis de inibidores da tirosina cinase do receptor, e métodos para a sua preparação
WO2016077371A1 (en) 2014-11-10 2016-05-19 Forsight Vision4, Inc. Expandable drug delivery devices and method of use
JP6674748B2 (ja) * 2015-05-27 2020-04-01 花王株式会社 Ｇｌｐ−１分泌促進剤
CA3005238A1 (en) 2015-11-20 2017-05-26 Forsight Vision4, Inc. Porous structures for extended release drug delivery devices
JP7009384B2 (ja) 2016-04-05 2022-01-25 フォーサイト・ビジョン フォー・インコーポレーテッド 移植可能な眼薬送達デバイス
CN105878194A (zh) * 2016-06-07 2016-08-24 沈阳药科大学 一种格列本脲纳米结晶制剂及其制备方法
EP4233840A3 (en) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
CN106362166B (zh) * 2016-10-27 2019-12-10 武汉大学 肿瘤坏死因子受体相关泛支架和信号蛋白在治疗脂肪肝和ⅱ型糖尿病中的功能和应用
KR20200093581A (ko) 2017-11-21 2020-08-05 포사이트 비젼4, 인크. 확장 가능한 포트 전달 시스템을 위한 유체 교환 기기 및 사용 방법
CN110006871A (zh) * 2019-02-20 2019-07-12 常州大学 一个基于外源性组胺检测的细胞模型以及应用
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005792A1 (de) * 1990-10-02 1992-04-16 Buchholz Klaus L Verwendung eines reaktionsproduktes aus einem gas und einer flüssigkeit, sowie verfahren und vorrichtung zu seiner herstellung
WO2002060458A2 (en) * 2001-02-01 2002-08-08 Hydron Technologies, Inc. Compositions and method of tissue superoxygenation
WO2006133113A2 (en) * 2005-06-03 2006-12-14 BAGLEY David System for making and conditioning super-oxygenated and structured water
WO2008052143A2 (en) * 2006-10-25 2008-05-02 Revalesio Corporation Mixing device and output fluids of same
WO2009055729A1 (en) * 2007-10-25 2009-04-30 Revalesio Corporation Compositions and methods for treating inflammation
WO2009055614A1 (en) * 2007-10-25 2009-04-30 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196164B2 (en) * 1997-07-08 2007-03-27 Human Genome Sciences, Inc. Secreted protein HHTLF25
US6861227B2 (en) * 1998-03-19 2005-03-01 Human Genome Sciences, Inc. Antibodies to cytokine receptor common gamma chain like
US6902902B2 (en) * 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
US8597689B2 (en) * 2006-10-25 2013-12-03 Revalesio Corporation Methods of wound care and treatment
US20080154795A1 (en) * 2006-12-25 2008-06-26 Amos Alon Auction platform and applications
JP2008156320A (ja) * 2006-12-26 2008-07-10 Hydrox Kk 抗酸化性機能水

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005792A1 (de) * 1990-10-02 1992-04-16 Buchholz Klaus L Verwendung eines reaktionsproduktes aus einem gas und einer flüssigkeit, sowie verfahren und vorrichtung zu seiner herstellung
WO2002060458A2 (en) * 2001-02-01 2002-08-08 Hydron Technologies, Inc. Compositions and method of tissue superoxygenation
WO2006133113A2 (en) * 2005-06-03 2006-12-14 BAGLEY David System for making and conditioning super-oxygenated and structured water
WO2008052143A2 (en) * 2006-10-25 2008-05-02 Revalesio Corporation Mixing device and output fluids of same
WO2009055729A1 (en) * 2007-10-25 2009-04-30 Revalesio Corporation Compositions and methods for treating inflammation
WO2009055614A1 (en) * 2007-10-25 2009-04-30 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2010126908A1 *

Also Published As

Publication number Publication date
WO2010126908A1 (en) 2010-11-04
IL215925A0 (en) 2011-12-29
MX2011011333A (es) 2011-11-18
CN102413817B (zh) 2014-12-17
EP2424507A1 (en) 2012-03-07
AU2010241736A1 (en) 2011-12-22
CA2758738A1 (en) 2010-11-04
AU2010241736B2 (en) 2016-01-28
JP2012525396A (ja) 2012-10-22
BRPI1013992A2 (pt) 2016-08-16
JP2015229678A (ja) 2015-12-21
CN102413817A (zh) 2012-04-11

Similar Documents

Publication Publication Date Title
EP2424507A4 (en) Compositions and methods for treating insulin resistance and diabetes mellitus
CY2023002I1 (el) Συνθεσεις και χρησεις για αντιμετωπιση πολλαπλης σκληρυνσης
EP2209371A4 (en) COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY
EP2201370A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TYPE-2 DIABETES
EP2717918A4 (en) COMPOSITION FOR THE TREATMENT OF DIABETES WITH A LONG-ACTING INSULIN CONJUGATE AND A LONG-ACTING INSULINOTROPIC PEPTIDE CONJUGATE
HUE038279T2 (hu) Klotho-béta-agonista antitest cukorbetegség vagy inzulinrezisztencia kezelésében történõ alkalmazásra
EP2069768A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TYPE-2 DIABETES
ZA201007114B (en) Compositions useful for the treatment of diabetes and other chronic disorder
EP2352517A4 (en) METHOD AND COMPOSITIONS FOR TREATING COMPLEMENT ASSOCIATED ILLNESSES
EP2480928A4 (en) MATERIALS FOR USE IN EYE MEDICINE APPLICATIONS AND METHOD THEREFOR
EP2330892A4 (en) TREATMENT PROCEDURE USING AMMONIA RECEIVER MEDICAMENTS
EP2271301A4 (en) METHOD AND COMPOSITIONS FOR THE DELIVERY OF FUNDS
EP2863910A4 (en) COMPOSITIONS AND METHOD FOR REGULATING GLUCOSE-HOMOSTOSTASE AND INSULIN EFFECT
EP2252312A4 (en) METHOD FOR PREVENTING OR TREATING INSULIN RESISTANCE
EP2464219A4 (en) MULTI-TRANSGENIC PIGS FOR DIABETES TREATMENT
PL2012765T3 (pl) Płynne kompozycje zawierające fenylefrynę i acetaminofen oraz ich zastosowanie do leczenia chorób układu oddechowego
PT2291654T (pt) Preparação e composição de proteínas inibidoras de interalfa do sangue
EP2155249A4 (en) COMPOSITIONS AND METHOD FOR DIAGNOSIS AND TREATMENT OF CANCER
EP2068865A4 (en) METHOD AND COMPOSITIONS FOR THERAPY TREATMENT
PL2205720T3 (pl) Kompozycja do leczenia stwardnienia rozsianego
EE201300007A (et) Kombineeritud ravimkoostis diabeedi ning ainevahetush„irete raviks
EP2349320A4 (en) COMPOSITIONS AND METHODS OF TREATING NURSE DISEASES
EP2067781A4 (en) MEANS FOR IMPROVING INSULIN RESISTANCE
EP2291957A4 (en) MEDIA PROCESSING POWER
EP2797619A4 (en) GLYPICAN-4 BASED COMPOSITIONS AND METHODS FOR TREATMENT AND DIAGNOSIS OF INSULIN RESISTANCE

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20111124

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20120926

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/02 20060101ALI20120920BHEP

Ipc: A61K 9/08 20060101ALI20120920BHEP

Ipc: A61K 31/58 20060101ALI20120920BHEP

Ipc: A61K 33/00 20060101ALI20120920BHEP

Ipc: A61K 9/00 20060101ALI20120920BHEP

Ipc: A61K 45/06 20060101ALI20120920BHEP

Ipc: A61K 9/14 20060101AFI20120920BHEP

17Q First examination report despatched

Effective date: 20151008

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20171103